Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only

Journal of Psychiatric Research

Volumn 47, Issue 7, 2013, Pages 908-915

  Haghighi, Mohammad ^a   Salehi, Iraj ^b   Erfani, Parichehr ^a   Jahangard, Leila ^a   Bajoghli, Hafez ^c   Holsboer Trachsler, Edith ^d   Brand, Serge ^d  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

BDNF; Citalopram; ECT; Major depressive disorders; Plasma

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON SCALE; HUMAN; HUMAN TISSUE; MAJOR DEPRESSION; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY;

EID: 84877128084     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.03.006     Document Type: Article

References (59)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC. 4th ed.
2. Barekatain M., Jahangard L., Haghighi M., Ranjkesh F. Bifrontal versus bitemporal electroconvulsive therapy in severe manic patients. Journal of ECT 2008, 24:199-202.
3. Beck A.T. Beck depression inventory 1961, Center for Cognitive Therapy, Philadelphia PA.
4. Beste C., Kolev V., Yordanova J., Domschke K., Falkenstein M., Baune B.T., et al. The role of the BDNF Val66Met polymorphism for the synchronization of error-specific neural networks. Journal of Neuroscience 2010, 30:10727-10733.
5. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
6. Bocchio-Chiavetto L., Zanardini R., Bortolomasi M., Abate M., Segala M., Giacopuzzi M., et al. Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. European Neuropsychopharmacology 2006, 16:620-624.
7. Bowley M.P., Drevets W.C., Ongür D., Price J.L. Low glial numbers in the amygdala in major depressive disorder. Biological Psychiatry 2002, 52:404-412.
8. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. American Journal of Psychiatry 2004, 161:598-607.
9. Castrén E., Ṽ ikar V., Rantamäki T. Role of neurotrophic factors in depression. Current Opinion in Pharmacology 2007, 7:18-21.
10. Chen F., Madsen T.M., Wegener G., Nyengaard J.R. Repeated electroconvulsive seizures increase the total number of synapses in adult male rat hippocampus. European Neuropsychopharmacology 2009, 19:329-338.
11. Cotter D., Mackay D., Landau S., Kerwin R., Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Archives of General Psychiatry 2001, 58:545-553.
12. Duman R.S., Monteggia L.M. Aneurotrophic model for stress-related mood disorders. Biological Psychiatry 2006, 59:1116-1127.
13. Esel E., Kose K., Hacimusalar Y., Ozsoy S., Kula M., Candan Z., et al. The effects of electroconvulsive therapy on GABAergic function in major depressive patients. Journal of ECT 2008, 24:224-228.
14. Fava G.A., Fabbri S., Sonino N. Residual symptoms in depression: an emerging therapeutic target. Progress in Neuropsychopharmacology and Biological Psychiatry 2002, 26:1019-1027.
15. Fernandes B., Gama C.S., Massuda R., Torres M., Camargo D., Kunz M., et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neuroscience Letter 2009, 453:195-198.
16. Gedge L., Beaudoin A., Lazowski L., du Toit R., Jokic R., Milev R. Effects of electroconvulsive therapy and repetitive transcranial magnetic stimulation on serum brain-derived neurotrophic factor levels in patients with depression. Frontiers in Psychiatry 2012, 3:12.
17. Giese M, Unternährer E, Hüttig H, Beck J, Brand S, Calabrese P, etal. BDNF - an indicator of insomnia? Molecular Psychiatry, in press.
18. Greden J.F. The burden of disease for treatment-resistant depression. Journal of Clinical Psychiatry 2001, 62:26-31.
19. Grønli O., Stensland G.Ø., Wynn R., Olstad R. Neurotrophic factors in serum following ECT: a pilot study. World Journal of Biological Psychiatry 2009, 10:295-301.
20. Guilloux J.P., Douillard-Guilloux G., Kota R., Wang X., Gardier A.M., Martinowich K., et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Molecular Psychiatry 2012, 17:1130-1142.
21. Haghighi M., Bajoghli H., Bigdelou G., Jahangard L., Holsboer-Trachsler E., Brand S. Assessment of cognitive impairments and seizure characteristics in electroconvulsive therapy with and without sodium valproate in manic patients. Neuropsychobiology 2013, 67:14-24.
22. Hamidi M., Drevets W.C., Price J.L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biological Psychiatry 2004, 55:563-569.
23. Hamilton M. Arating scale for depression. Journal of Neurolology, Neurosurgery and Psychiatry 1960, 23:56-62.
24. Harker L.A., Roskos L.K., Marzec U.M., Carter R.A., Cherry J.K., Sundell B., et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000, 95:2514-2522.
25. Heninger G.R., Delgado P.L., Charney D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996, 29:2-11.
26. Hibel L.C., Senguttuvan U., Bauer N.S. Do state factors moderate the relationship between depressive symptoms and morning cortisol?. Hormones and Behavior 2013, 63:484-490.
27. Holaday J.W., Tortella F.C., Long J.B., Belenky G.L., Hitzemann R.J. Endogenous opioids and their receptors: evidence for involvement in the postictal effects of electroconvulsive shock. Annals of the New York Academy of Science 1986, 462:124-139.
28. Holsboer F., Ising M. Stress hormone regulation: biological role and translation into therapy. Annual Review of Psychology 2010, 61:81-109.
29. Jenkins E., Goldner E.M. Approaches to understanding and addressing treatment-resistant depression: a scoping review. Depression Research and Treatment 2012, 469680.
30. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders 1998, 50:97-108.
31. Kamil R., Joffe R.T. Neuroendocrine testing in electroconvulsive therapy. Psychiatric Clinics of North America 1991, 14:961-970.
32. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research 2002, 109:143-148.
33. Keitner G.I., Mansfield A.K. Management of treatment-resistant depression. Psychiatric Clinics of North America 2012, 35:249-265.
34. Kellner C.H., Greenberg R.M., Murrough J.W., Bryson E.O., Briggs M.C., Pasculli R.M. ECT in Treatment-Resistant Depression. American Journal of Psychiatry 2012, 169:1238-1244.
35. Kennedy N., Paykel E.S. Residual symptoms at remission from depression: impact on long-term outcome. Journal of Affective Disorders 2004, 80:135-144.
36. Madsen T.M., Treschow A., Bengzon J., Bolwig T.G., Lindvall O., Tingström A. Increased neurogenesis in a model of electroconvulsive therapy. Biological Psychiatry 2000, 47:1043-1049.
37. Mamounas L.A., Blue M.E., Siuciak J.A., Altar C.A. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. Journal of Neuroscience 1995, 15:7929-7939.
38. Marano C.M., Phatak P., Vemulapalli U.R., Sasan A., Nalbandyan M.R., Ramanujam S., et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. Journal of Clinical Psychiatry 2007, 68:512-517.
39. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. Journal of Psychiatric Research 2009, 43:247-254.
40. Naert G., Ixart G., Maurice T., Tapia-Arancibia L., Givalois L. Brain-derived neurotrophic factor and hypothalamic-pituitary-adrenal axis adaptation processes in a depressive-like state induced by chronic restraint stress. Molecular and Cellular Neurosciences 2011, 46:55-66.
41. Numakawa T, Adachi N, Richards M, Chiba S, Kunugi H. Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience, in press.
42. Pfleiderer B., Michael N., Erfurth A., Ohrmann P., Hohmann U., Wolgast M., et al. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Researc 2003, 122:185-192.
43. Piccinni A., Del Debbio A., Medda P., Bianchi C., Roncaglia I., Veltri A., et al. Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. European Neuropsychopharmacology 2009, 19:349-355.
44. Poduslo J.F., Curran G.L. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Research. Molecular Brain Research 1996, 36:280-286.
45. Rajkowska G., Halaris A., Selemon L.D. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biological Psychiatry 2001, 49:741-752.
46. Reid I.C., Stewart C.A. How antidepressants work: new perspectives on the pathophysiology of depressive disorder. British Journal of Psychiatry 2001, 178:299-303.
47. Reid I.C., Stewart C.A. Seizures, memory and synaptic plasticity. Seizure 1997, 6:351-359.
48. Sackeim H.A. The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. Journal of ECT 1999, 15:5-26.
49. Sackeim H.A. The definition and meaning of treatment-resistant depression. Journal of Clinical Psychiatry 2001, 62:10-17.
50. Scott B.W., Wojtowicz J.M., Burnham W.M. Neurogenesis in the dentate gyrus of the rat following electroconvulsive shock seizures. Experimental Neurology 2000, 165:231-236.
51. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry 2008, 64:527-532.
52. Serra-Millàs M., López-Vílchez I., Navarro V., Galán A.M., Escolar G., Penadés R., et al. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression. Psychopharmacology 2011, 216:1-8.
53. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. Journal of Neuroscience 2002, 22:3251-3261.
54. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacology, Biochemistry and Behavior 1997, 56:131-137.
55. Taylor M.A., Fink M. Melancholia: the diagnosis, pathophysiology, and treatment of depressive illness 2006, Cambridge University Press, New York NY.
56. UK ECT Review Group Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003, 361:799-808.
57. Videbech P., Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. American Journal of Psychiatry 2004, 161:1957-1966.
58. Wahlund B., von Rosen D. ECT of major depressed patients in relation to biological and clinical variables: a brief overview. Neuropsychopharmacology 2003, 28(Suppl. 1):S21-S26.
59. Wolkowitz O.M., Wolf J., Shelly W., Rosser R., Burke H.M., Lerner G.K., et al. Serum BDNF levels before treatment predict SSRI response in depression. Progress in Neuropsychopharmacology and Biological Psychiatry 2011, 35:1623-1630.